Borg, Brian

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension

Chalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 358

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis

LOOMBA, R., LUTCHMAN, G., KLEINER, D. E., RICKS, M., FELD, J. J., BORG, B. B., MODI, A., NAGABHYRU, P., SUMNER, A. E., LIANG, T. J., et al. (2009) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 299

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Loomba, R., Noureddin, M., Kowdley, K. V., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N., Caldwell, S. H., Goodman, Z., et al. (2021) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 296

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis

Siddiqui, M. S., Idowu, M. O., Parmar, D., Borg, B. B., Denham, D., Loo, N. M., Lazas, D., Younes, Z., & Sanyal, A. J. (2021) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 96

Queue position in the endoscopic schedule impacts effectiveness of colonoscopy

Lee, A., Iskander, J. M., Gupta, N., Borg, B. B., Zuckerman, G., Banerjee, B., & Gyawali, P. C. (2011) · American Journal of Gastroenterology

Colorectal Cancer Screening and DetectionHospital Admissions and Outcomes

Cited by 66

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 39

Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial

Loomba, R., Noureddin, M., Kowdley, K., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N. T., Caldwell, S., Goodman, Z., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentOrgan Transplantation Techniques and Outcomes

Cited by 9